Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

被引：0
|
作者：
Qin, Shukui
Bai, Yuxian
Wang, Zishu
Chen, Zhendong
Xu, Ruihua
Xu, Jianming
Zhang, Hongmei
Chen, Jia
Yuan, Ying
Liu, Tianshu
Yang, Lin
Zhong, Haijun
Chen, Donghui
Shen, Lin
Hao, Chunyi
Fu, Deliang
Cheng, Ying
Yang, Jianwei
Bai, Xian Hong
Li, Jin
机构：
[1] Jinling Hosp, Ctr Canc, Dept Med Oncol, Nanjing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Anhui Med Univ, Hosp 2, Hefei, Anhui, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[6] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[7] Air Force Med Univ PLA, Xijing Hosp, Xian, Peoples R China
[8] Jiangsu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[9] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[12] Univ Chinese Acad Sci, Chinese Acad Sci, Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med,Canc Hos, Hangzhou, Peoples R China
[13] Shanghai Jiao Tong Univ, Peoples Hosp 1, Sch Med, Dept Oncol, Shanghai, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[15] Beijing Canc Hosp, Beijing, Peoples R China
[16] Fudan Univ, Pancreat Dis Inst, Huashan Hosp, Dept Pancreat Surg, Shanghai, Peoples R China
[17] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[18] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Peoples R China
[19] Biotech Pharmaceut Ltd Corp, Beijing, Peoples R China
[20] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study.
    Viret, F
    Ychou, M
    Lepille, D
    Mineur, L
    Navarro, F
    Topart, D
    Fonck, M
    Goineau, J
    Madroszyk-Flandin, A
    Chouaki, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 342S - 342S
  • [22] Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).
    Meng, Xue
    Zheng, Anping
    Wang, Jun
    Wang, Jianhua
    Li, Guang
    Zhu, Jun
    Ma, Hu
    Zhu, Xiaodong
    Shi, Anhui
    Dai, Chunhua
    Yan, Senxiang
    Wang, Buhai
    Qu, Zhongyu
    Han, Chun
    Sun, Xindong
    Ye, Ming
    Fan, Ruitai
    Huerxidan, Ni Yazi
    Wang, Xiaohong
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer:: A multicenter phase II trial.
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stötzer, O.
    Mueller, E.
    Depenbrock, H.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
  • [24] Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
    Xu, Rui-Hua
    Shen, Lin
    Wang, Ke-Ming
    Wu, Gang
    Shi, Chun-Mei
    Ding, Ke-Feng
    Lin, Li-Zhu
    Wang, Jin-Wan
    Xiong, Jian-Ping
    Wu, Chang-Ping
    Li, Jin
    Liu, Yun-Peng
    Wang, Dong
    Ba, Yi
    Feng, Jue-Ping
    Bai, Yu-Xian
    Bi, Jing-Wang
    Ma, Li-Wen
    Lei, Jian
    Yang, Qing
    Yu, Hao
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [25] BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Goncalves, A.
    Viret, F.
    Francois, E.
    Dahan, L.
    Perrier, H.
    Lamy, R.
    Re, D.
    Largillier, R.
    Gasmi, M.
    Tchiknavorian, X.
    Turrini, O.
    Moureau-Zabotto, L.
    Delpero, J.
    Viens, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.
    Bendell, Johanna C.
    Peyton, James D.
    Sommers, Scott Ryan
    Xiong, Henry D.
    Crane, Edward J.
    Harwin, William N.
    Kozloff, Mark
    Shipley, Dianna
    Thompson, Dana Shelton
    Womack, Mark
    Jones, Suzanne Fields
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS
    Riess, H.
    Manges, R.
    Karasek, P.
    Humblet, Y.
    Barono, C.
    Santoro, A.
    Wojcik-Tomaszewska, J.
    Assadourian, S.
    Hatteville, L.
    Vincent, G.
    Philip, P.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [28] Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
    Herrmann, Richard
    Bodoky, Gyoergy
    Ruhstaller, Thomas
    Glimelius, Bengt
    Bajetta, Emilio
    Schueller, Johannes
    Saletti, Piercarlo
    Bauer, Jean
    Figer, Arie
    Pestalozzi, Bernhard
    Koehne, Claus-Henning
    Mingrone, Walter
    Stemmer, Salomon M.
    Tamas, Karin
    Kornek, Gabriela V.
    Koeberle, Dieter
    Cina, Susanne
    Bernhard, Juerg
    Dietrich, Daniel
    Scheithauer, Werner
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2212 - 2217
  • [29] QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
    Guo, Weijian
    Wang, Yusheng
    Yang, Wenhui
    Li, Yunfeng
    Zhang, Yanqiao
    Zhang, Zhongtao
    Xiong, Hailin
    Li, Changzheng
    Wang, Zhiwu
    Fan, Nanfeng
    Yin, Xianli
    Du, Peng
    Luo, Suxia
    Zhang, Jingdong
    Yu, Dajun
    Zheng, Weie
    Kang, Xiaoyan
    Mao, Kaisheng
    Wang, Zhan
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 190 - 190
  • [30] A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer
    Sun, Y.
    Li, Y.
    Qin, S.
    Ma, D.
    Jiao, S. C.
    Yu, S. Y.
    Li, J.
    Liu, D.
    Song, D.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345